Gastrointestinal Stromal Tumors (GISTs) Treatment Market Report

Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Feb 25, 2022
  • PAGES：145
  • REPORT CODE：GMM778163
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Gastrointestinal Stromal Tumors (GISTs) Treatment market report explains the definition, types, applications, major countries, and major players of the Gastrointestinal Stromal Tumors (GISTs) Treatment market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Boston Biomedical

    • Novartis

    • Immunicum

    • Arog Pharmaceuticals

    • Pfizer

    • AB Science

    • Sun Pharmaceutical

    • Natco Pharma

    • Bayer

    • Roche

    By Type:

    • Surgery

    • Targeted Therapy

    • Radiation Therapy

    • Chemotherapy

    • Ablation

    • Embolization

    • Others

    By End-User:

    • Hospitals

    • Clinics

    • Ambulatory Surgical Centers

    • Others

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Gastrointestinal Stromal Tumors (GISTs) Treatment Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Gastrointestinal Stromal Tumors (GISTs) Treatment Outlook to 2028- Original Forecasts

    • 2.2 Gastrointestinal Stromal Tumors (GISTs) Treatment Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Gastrointestinal Stromal Tumors (GISTs) Treatment Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market- Recent Developments

    • 6.1 Gastrointestinal Stromal Tumors (GISTs) Treatment Market News and Developments

    • 6.2 Gastrointestinal Stromal Tumors (GISTs) Treatment Market Deals Landscape

    7 Gastrointestinal Stromal Tumors (GISTs) Treatment Raw Materials and Cost Structure Analysis

    • 7.1 Gastrointestinal Stromal Tumors (GISTs) Treatment Key Raw Materials

    • 7.2 Gastrointestinal Stromal Tumors (GISTs) Treatment Price Trend of Key Raw Materials

    • 7.3 Gastrointestinal Stromal Tumors (GISTs) Treatment Key Suppliers of Raw Materials

    • 7.4 Gastrointestinal Stromal Tumors (GISTs) Treatment Market Concentration Rate of Raw Materials

    • 7.5 Gastrointestinal Stromal Tumors (GISTs) Treatment Cost Structure Analysis

      • 7.5.1 Gastrointestinal Stromal Tumors (GISTs) Treatment Raw Materials Analysis

      • 7.5.2 Gastrointestinal Stromal Tumors (GISTs) Treatment Labor Cost Analysis

      • 7.5.3 Gastrointestinal Stromal Tumors (GISTs) Treatment Manufacturing Expenses Analysis

    8 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Export by Region (Top 10 Countries) (2017-2028)

    9 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Outlook by Types and Applications to 2022

    • 9.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Surgery Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Targeted Therapy Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Radiation Therapy Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Chemotherapy Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Ablation Consumption and Growth Rate (2017-2022)

      • 9.1.6 Global Embolization Consumption and Growth Rate (2017-2022)

      • 9.1.7 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Ambulatory Surgical Centers Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Others Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Gastrointestinal Stromal Tumors (GISTs) Treatment Market Analysis and Outlook till 2022

    • 10.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.2.2 Canada Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.2.3 Mexico Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.3.2 UK Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.3.3 Spain Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.3.4 Belgium Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.3.5 France Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.3.6 Italy Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.3.7 Denmark Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.3.8 Finland Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.3.9 Norway Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.3.10 Sweden Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.3.11 Poland Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.3.12 Russia Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.3.13 Turkey Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.4.2 Japan Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.4.3 India Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.4.4 South Korea Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.4.5 Pakistan Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.4.6 Bangladesh Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.4.7 Indonesia Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.4.8 Thailand Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.4.9 Singapore Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.4.10 Malaysia Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.4.11 Philippines Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.4.12 Vietnam Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.5.2 Colombia Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.5.3 Chile Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.5.4 Argentina Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.5.5 Venezuela Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.5.6 Peru Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.5.7 Puerto Rico Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.5.8 Ecuador Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.6.2 Kuwait Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.6.3 Oman Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.6.4 Qatar Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.7.2 South Africa Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.7.3 Egypt Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.7.4 Algeria Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

      • 10.8.2 New Zealand Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption (2017-2022)

    11 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Competitive Analysis

    • 11.1 Boston Biomedical

      • 11.1.1 Boston Biomedical Company Details

      • 11.1.2 Boston Biomedical Gastrointestinal Stromal Tumors (GISTs) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Boston Biomedical Gastrointestinal Stromal Tumors (GISTs) Treatment Main Business and Markets Served

      • 11.1.4 Boston Biomedical Gastrointestinal Stromal Tumors (GISTs) Treatment Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Novartis

      • 11.2.1 Novartis Company Details

      • 11.2.2 Novartis Gastrointestinal Stromal Tumors (GISTs) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Novartis Gastrointestinal Stromal Tumors (GISTs) Treatment Main Business and Markets Served

      • 11.2.4 Novartis Gastrointestinal Stromal Tumors (GISTs) Treatment Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Immunicum

      • 11.3.1 Immunicum Company Details

      • 11.3.2 Immunicum Gastrointestinal Stromal Tumors (GISTs) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Immunicum Gastrointestinal Stromal Tumors (GISTs) Treatment Main Business and Markets Served

      • 11.3.4 Immunicum Gastrointestinal Stromal Tumors (GISTs) Treatment Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Arog Pharmaceuticals

      • 11.4.1 Arog Pharmaceuticals Company Details

      • 11.4.2 Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GISTs) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GISTs) Treatment Main Business and Markets Served

      • 11.4.4 Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GISTs) Treatment Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Pfizer

      • 11.5.1 Pfizer Company Details

      • 11.5.2 Pfizer Gastrointestinal Stromal Tumors (GISTs) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Pfizer Gastrointestinal Stromal Tumors (GISTs) Treatment Main Business and Markets Served

      • 11.5.4 Pfizer Gastrointestinal Stromal Tumors (GISTs) Treatment Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 AB Science

      • 11.6.1 AB Science Company Details

      • 11.6.2 AB Science Gastrointestinal Stromal Tumors (GISTs) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 AB Science Gastrointestinal Stromal Tumors (GISTs) Treatment Main Business and Markets Served

      • 11.6.4 AB Science Gastrointestinal Stromal Tumors (GISTs) Treatment Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Sun Pharmaceutical

      • 11.7.1 Sun Pharmaceutical Company Details

      • 11.7.2 Sun Pharmaceutical Gastrointestinal Stromal Tumors (GISTs) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Sun Pharmaceutical Gastrointestinal Stromal Tumors (GISTs) Treatment Main Business and Markets Served

      • 11.7.4 Sun Pharmaceutical Gastrointestinal Stromal Tumors (GISTs) Treatment Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Natco Pharma

      • 11.8.1 Natco Pharma Company Details

      • 11.8.2 Natco Pharma Gastrointestinal Stromal Tumors (GISTs) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Natco Pharma Gastrointestinal Stromal Tumors (GISTs) Treatment Main Business and Markets Served

      • 11.8.4 Natco Pharma Gastrointestinal Stromal Tumors (GISTs) Treatment Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 Bayer

      • 11.9.1 Bayer Company Details

      • 11.9.2 Bayer Gastrointestinal Stromal Tumors (GISTs) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 Bayer Gastrointestinal Stromal Tumors (GISTs) Treatment Main Business and Markets Served

      • 11.9.4 Bayer Gastrointestinal Stromal Tumors (GISTs) Treatment Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    • 11.10 Roche

      • 11.10.1 Roche Company Details

      • 11.10.2 Roche Gastrointestinal Stromal Tumors (GISTs) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.10.3 Roche Gastrointestinal Stromal Tumors (GISTs) Treatment Main Business and Markets Served

      • 11.10.4 Roche Gastrointestinal Stromal Tumors (GISTs) Treatment Product Portfolio

      • 11.10.5 Recent Research and Development Strategies

    12 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Outlook by Types and Applications to 2028

    • 12.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Surgery Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Targeted Therapy Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Radiation Therapy Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.5 Global Ablation Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.6 Global Embolization Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.7 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Ambulatory Surgical Centers Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.4 Global Others Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Gastrointestinal Stromal Tumors (GISTs) Treatment Market Analysis and Outlook to 2028

    • 13.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.2.2 Canada Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.3.2 UK Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.3.3 Spain Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.3.5 France Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.3.6 Italy Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.3.8 Finland Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.3.9 Norway Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.3.11 Poland Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.3.12 Russia Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.4.2 Japan Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.4.3 India Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.5.3 Chile Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.5.6 Peru Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.6.3 Oman Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Gastrointestinal Stromal Tumors (GISTs) Treatment

    • Figure of Gastrointestinal Stromal Tumors (GISTs) Treatment Picture

    • Table Global Gastrointestinal Stromal Tumors (GISTs) Treatment Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Gastrointestinal Stromal Tumors (GISTs) Treatment Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Surgery Consumption and Growth Rate (2017-2022)

    • Figure Global Targeted Therapy Consumption and Growth Rate (2017-2022)

    • Figure Global Radiation Therapy Consumption and Growth Rate (2017-2022)

    • Figure Global Chemotherapy Consumption and Growth Rate (2017-2022)

    • Figure Global Ablation Consumption and Growth Rate (2017-2022)

    • Figure Global Embolization Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Clinics Consumption and Growth Rate (2017-2022)

    • Figure Global Ambulatory Surgical Centers Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption by Country (2017-2022)

    • Table North America Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption by Country (2017-2022)

    • Figure United States Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Canada Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Mexico Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Table Europe Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption by Country (2017-2022)

    • Figure Germany Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure UK Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Spain Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Belgium Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure France Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Italy Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Denmark Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Finland Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Norway Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Sweden Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Poland Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Russia Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Turkey Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Table APAC Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption by Country (2017-2022)

    • Figure China Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Japan Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure India Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Korea Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Thailand Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Singapore Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Philippines Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Table South America Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption by Country (2017-2022)

    • Figure Brazil Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Colombia Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Chile Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Argentina Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Peru Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Table GCC Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption by Country (2017-2022)

    • Figure Bahrain Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Oman Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Qatar Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Table Africa Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption by Country (2017-2022)

    • Figure Nigeria Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Africa Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Egypt Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Algeria Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Table Oceania Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption by Country (2017-2022)

    • Figure Australia Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption and Growth Rate (2017-2022)

    • Table Boston Biomedical Company Details

    • Table Boston Biomedical Gastrointestinal Stromal Tumors (GISTs) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Boston Biomedical Gastrointestinal Stromal Tumors (GISTs) Treatment Main Business and Markets Served

    • Table Boston Biomedical Gastrointestinal Stromal Tumors (GISTs) Treatment Product Portfolio

    • Table Novartis Company Details

    • Table Novartis Gastrointestinal Stromal Tumors (GISTs) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis Gastrointestinal Stromal Tumors (GISTs) Treatment Main Business and Markets Served

    • Table Novartis Gastrointestinal Stromal Tumors (GISTs) Treatment Product Portfolio

    • Table Immunicum Company Details

    • Table Immunicum Gastrointestinal Stromal Tumors (GISTs) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Immunicum Gastrointestinal Stromal Tumors (GISTs) Treatment Main Business and Markets Served

    • Table Immunicum Gastrointestinal Stromal Tumors (GISTs) Treatment Product Portfolio

    • Table Arog Pharmaceuticals Company Details

    • Table Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GISTs) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GISTs) Treatment Main Business and Markets Served

    • Table Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GISTs) Treatment Product Portfolio

    • Table Pfizer Company Details

    • Table Pfizer Gastrointestinal Stromal Tumors (GISTs) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Gastrointestinal Stromal Tumors (GISTs) Treatment Main Business and Markets Served

    • Table Pfizer Gastrointestinal Stromal Tumors (GISTs) Treatment Product Portfolio

    • Table AB Science Company Details

    • Table AB Science Gastrointestinal Stromal Tumors (GISTs) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table AB Science Gastrointestinal Stromal Tumors (GISTs) Treatment Main Business and Markets Served

    • Table AB Science Gastrointestinal Stromal Tumors (GISTs) Treatment Product Portfolio

    • Table Sun Pharmaceutical Company Details

    • Table Sun Pharmaceutical Gastrointestinal Stromal Tumors (GISTs) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sun Pharmaceutical Gastrointestinal Stromal Tumors (GISTs) Treatment Main Business and Markets Served

    • Table Sun Pharmaceutical Gastrointestinal Stromal Tumors (GISTs) Treatment Product Portfolio

    • Table Natco Pharma Company Details

    • Table Natco Pharma Gastrointestinal Stromal Tumors (GISTs) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Natco Pharma Gastrointestinal Stromal Tumors (GISTs) Treatment Main Business and Markets Served

    • Table Natco Pharma Gastrointestinal Stromal Tumors (GISTs) Treatment Product Portfolio

    • Table Bayer Company Details

    • Table Bayer Gastrointestinal Stromal Tumors (GISTs) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer Gastrointestinal Stromal Tumors (GISTs) Treatment Main Business and Markets Served

    • Table Bayer Gastrointestinal Stromal Tumors (GISTs) Treatment Product Portfolio

    • Table Roche Company Details

    • Table Roche Gastrointestinal Stromal Tumors (GISTs) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Roche Gastrointestinal Stromal Tumors (GISTs) Treatment Main Business and Markets Served

    • Table Roche Gastrointestinal Stromal Tumors (GISTs) Treatment Product Portfolio

    • Figure Global Surgery Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Targeted Therapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Radiation Therapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Ablation Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Embolization Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Ambulatory Surgical Centers Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast by Country (2022-2028)

    • Table North America Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast by Country (2022-2028)

    • Figure United States Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Germany Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast by Country (2022-2028)

    • Figure China Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Brazil Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Australia Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Gastrointestinal Stromal Tumors (GISTs) Treatment Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US